Despite the promotion of FAK expression by the APC disruption‐linked MYC activation, [9] FAK may be largely activated in CRC through the ECM‐integrin engagement, as the pharmacological inhibitor targeting active FAK (VS‐6063) markedly impairs cell proliferation in several cell lines examined (Figure 3). This evidence concerns the gene PTK2 and colorectal carcinoma.